Escitalopram Dose Optimization During Pregnancy: A PBPK Modeling Approach

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Reproductive Toxicology
• Computational Pharmacology

Background:

• Escitalopram, a common antidepressant, undergoes metabolism primarily via CYP2C19.
• Pregnancy significantly alters drug pharmacokinetics, affecting both maternal and fetal exposure.
• Understanding escitalopram's behavior during gestation is crucial for safe and effective treatment.

Purpose of the Study:

• To predict maternal and fetal exposure to escitalopram during pregnancy using PBPK modeling.
• To develop evidence-based, safe, and effective escitalopram dosing strategies for pregnancy.
• To investigate the influence of CYP2C19 phenotypes on escitalopram pharmacokinetics in pregnancy.

Main Methods:

• Development of predictive PBPK models for escitalopram in nonpregnant and pregnant women, and the fetoplacental unit.
• Utilized the Simcyp® simulator for model construction, incorporating CYP2C19 phenotypes.
• Model validation through visual predictive checks and comparison of predicted-to-observed Cmax and AUC ratios.

Main Results:

• Escitalopram concentrations decreased with advancing gestational age for 10-20 mg doses.
• The cord-to-maternal concentration ratio was consistently around 0.70.
• Simulations across CYP2C19 phenotypes demonstrated good agreement between predicted and observed concentrations.

Conclusions:

• A once-daily 20 mg dose of escitalopram is predicted to be optimal during pregnancy.
• Gestational stage and individual CYP2C19 metabolic status are critical factors for escitalopram dose optimization.
• PBPK modeling provides a valuable tool for guiding antidepressant dosing in pregnant populations.